Press Releases

Date	Title and Summary	Additional Formats
Toggle Summary Aug 18, 2015	Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 SOLANA BEACH, Calif. , Aug. 18, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating the agency's	View HTML Evoke Receives Favorable Response From U.S. Food and Drug Administration Regarding Pediatric Study Plan for EVK-001 16.6 KB
Toggle Summary May 20, 2020	Evoke Receives FDA Conditional Acceptance of Gimoti Brand Name Following NDA Resubmission SOLANA BEACH, Calif. , May 20, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary brand	View HTML PDF Version
Toggle Summary Dec 15, 2016	Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data	View HTML Evoke Receives Positive NDA Submission Guidance from US FDA for Gimoti 16.2 KB
Toggle Summary Dec 20, 2019	Evoke Resubmits Gimoti™ New Drug Application to FDA SOLANA BEACH, Calif. , Dec. 20, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S.	View HTML PDF Version
Toggle Summary Apr 25, 2016	Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis SOLANA BEACH, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), today announced that it has successfully completed patient enrollment in its pivotal Phase 3 clinical trial of EVK-001, its patented nasal delivery formulation of metoclopramide for the relief of symptoms	View HTML Evoke Successfully Completes Phase 3 Clinical Trial Enrollment of EVK-001 in Women with Symptoms Associated with Diabetic Gastroparesis 17.9 KB
Toggle Summary Nov 10, 2015	Evoke to Participate in the Brean Capital 2015 Life Sciences Summit SOLANA BEACH, Calif. , Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer , R.Ph., President and CEO will be participating in the Brean Capital 2015 Life	View HTML Evoke to Participate in the Brean Capital 2015 Life Sciences Summit 15.3 KB
Toggle Summary Jan 21, 2020	FDA Accepts Evoke Pharma’s NDA Resubmission for Gimoti™ PDUFA Target Goal Date is June 19, 2020 SOLANA BEACH, Calif. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on the development of drugs to treat gastrointestinal (GI) disorders and diseases, today announced that the U.S.	View HTML PDF Version
Toggle Summary Jun 19, 2020	FDA Approves Evoke’s GIMOTI™ Commercial Partner EVERSANA Prepares for GIMOTI Launch Evoke Extends Cash Runway into 2021 SOLANA BEACH, Calif. , June 19, 2020 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that	View HTML PDF Version
Toggle Summary Mar 05, 2018	FDA Approves PDUFA Fee Waiver for Gimoti™ New Drug Application Cash runway updated into October 2018 SOLANA BEACH, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ:EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the U.S.	View HTML PDF Version
Toggle Summary Feb 15, 2017	FDA Exempts Evoke from Requirement for Human Factor Validation Study Company reaffirms NDA submission by year end 2017	View HTML FDA Exempts Evoke from Requirement for Human Factor Validation Study 194 KB